- Home
- CHNR vs CVKD Comparison
CHNR vs CVKD Comparison
Compare CHNR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- CVKD
- Stock Information
- Founded
- CHNR N/A
- CVKD 2022
- Country
- CHNR Hong Kong
- CVKD United States
- Employees
- CHNR N/A
- CVKD N/A
- Industry
- CHNR Precious Metals
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CHNR Basic Materials
- CVKD Health Care
- Exchange
- CHNR Nasdaq
- CVKD Nasdaq
- Market Cap
- CHNR 6.4M
- CVKD 17.1M
- IPO Year
- CHNR 1995
- CVKD 2023
- Fundamental
- Price
- CHNR $0.79
- CVKD $15.24
- Analyst Decision
- CHNR
- CVKD Strong Buy
- Analyst Count
- CHNR 0
- CVKD 2
- Target Price
- CHNR N/A
- CVKD $52.50
- AVG Volume (30 Days)
- CHNR 148.0K
- CVKD 59.6K
- Earning Date
- CHNR 01-01-0001
- CVKD 11-08-2024
- Dividend Yield
- CHNR N/A
- CVKD N/A
- EPS Growth
- CHNR N/A
- CVKD N/A
- EPS
- CHNR N/A
- CVKD N/A
- Revenue
- CHNR N/A
- CVKD N/A
- Revenue This Year
- CHNR N/A
- CVKD N/A
- Revenue Next Year
- CHNR N/A
- CVKD N/A
- P/E Ratio
- CHNR N/A
- CVKD N/A
- Revenue Growth
- CHNR N/A
- CVKD N/A
- 52 Week Low
- CHNR $0.55
- CVKD $5.40
- 52 Week High
- CHNR $8.85
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- CHNR 53.35
- CVKD 60.90
- Support Level
- CHNR $0.68
- CVKD $11.19
- Resistance Level
- CHNR $0.83
- CVKD $15.93
- Average True Range (ATR)
- CHNR 0.10
- CVKD 1.36
- MACD
- CHNR -0.00
- CVKD 0.23
- Stochastic Oscillator
- CHNR 24.60
- CVKD 61.01
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.